Monoclonal antibodies

Illustration of a virus
#Biomedical Advanced Research and Development Authority (BARDA) #Evotec #Monoclonal antibodies #Pandemic prevention

Just – Evotec Biologics enters $10m agreement with BARDA

Evotec’s subsidiary and CDMO, Just – Evotec Biologics, has been selected by the Biomedical Advanced Research and Development Authority (BARDA) Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium) to advance manufacturing optimisation for a monoclonal antibody cocktail.  The therapy will target filovirus diseases, including Ebola virus (EBOV) and Sudan virus (SUDV).  The multi-year… Read More

#Business & Investment #News

#Antibody drug conjugate (ADC) #LC-MS #Monoclonal antibodies #Oligonucleotides #Webinar

Last chance to register: Understand LC-MS quantification strategies for proteins

A new event, hosted by DDW and supported by Evotec, will explore cutting-edge LC-MS-based bioanalytical approaches tailored for the quantitative analysis of therapeutic proteins, such as monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), fusion protein biomarkers, and oligonucleotides in biological fluids and tissues. The webinar, taking place on 27 March, will… Read More

Webinar date:
Supported by Evotec
#News

#Antibody drug conjugate (ADC) #LC-MS #Monoclonal antibodies #Oligonucleotides #Webinar

Webinar: Learn about LC-MS-based bioanalytical approaches

A new event, hosted by DDW and supported by Evotec, will explore cutting-edge LC-MS-based bioanalytical approaches tailored for the quantitative analysis of therapeutic proteins, such as monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), fusion protein biomarkers, and oligonucleotides in biological fluids and tissues. The webinar, taking place on 27 March, will… Read More

Webinar date:
Supported by Evotec
#News

#Clinical trial #Infertility #Monoclonal antibodies

A new approach to treating infertility

DDW Editor Reece Armstrong speaks to Elke Bestel, Chief Medical Officer at Igyxos, about the treatment space for infertility and how the company’s monoclonal antibody IGX12 could represent a differentiated approach.   RA: Why have treatments for infertility remained limited?  EB: Developing treatments for infertility has been and is still complex. First of all, infertility can result from hormonal, anatomical, metabolic,… Read More

#Exclusive Content

European Commission
#European Commission #Incyte #Monoclonal antibodies #Oncology

European Commission approves retifanlimab for anal cancer

The European Commission (EC) has approved Zynyz (retifanlimab) in combination with carboplatin and paclitaxel for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC).  Rretifanlimab is the first systemic treatment for adult patients with advanced SCAC in Europe. … Read More

#News #Regulatory

Antibody drug conjugate
#Antibody drug conjugate (ADC) #LC-MS #Monoclonal antibodies #Oligonucleotides #Webinar

Register now to understand advanced LC-MS bioanalytical strategies for biologics

A new event, hosted by DDW and supported by Evotec, will explore cutting-edge LC-MS-based bioanalytical approaches tailored for the quantitative analysis of therapeutic proteins, such as monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), fusion protein biomarkers, and oligonucleotides in biological fluids and tissues. The webinar, taking place on 27 March, will… Read More

Webinar date:
Supported by Evotec
#News

Monoclonal antibodies
#Antibody drug conjugate (ADC) #LC-MS #Monoclonal antibodies #Oligonucleotides #Webinar

Webinar: Quantitative analysis of therapeutic proteins

A new event, hosted by DDW and supported by Evotec, will explore cutting-edge LC-MS-based bioanalytical approaches tailored for the quantitative analysis of therapeutic proteins, such as monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), fusion protein biomarkers, and oligonucleotides in biological fluids and tissues. The webinar, taking place on 27 March, will… Read More

Webinar date:
Supported by Evotec
#News

Biologic drugs
#Antibody drug conjugate (ADC) #LC-MS #Monoclonal antibodies #Oligonucleotides #Webinar

Webinar: Explore cutting-edge LC-MS-based bioanalytical approaches

A new event, hosted by DDW and supported by Evotec, will explore cutting-edge LC-MS-based bioanalytical approaches tailored for the quantitative analysis of therapeutic proteins, such as monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), fusion protein biomarkers, and oligonucleotides in biological fluids and tissues. The webinar, taking place on 27 March, will… Read More

Webinar date:
Supported by Evotec
#News

#Antibody drug conjugate (ADC) #LC-MS #Monoclonal antibodies #Oligonucleotides #Webinar

Webinar: Advanced LC-MS bioanalytical strategies for biologics

A new event, hosted by DDW and supported by Evotec, will explore cutting-edge LC-MS-based bioanalytical approaches tailored for the quantitative analysis of therapeutic proteins, such as monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), fusion protein biomarkers, and oligonucleotides in biological fluids and tissues. The webinar, taking place on 27 March, will… Read More

Webinar date:
Supported by Evotec
#News

#Antibody drug conjugate (ADC) #LC-MS #Monoclonal antibodies #Oligonucleotides #Webinar

Advanced LC-MS bioanalytical strategies for biologics: mAbs, ADCs, and oligonucleotides in complex biological matrices

This event, hosted by DDW and supported by Evotec, will explore cutting-edge LC-MS-based bioanalytical approaches tailored for the quantitative analysis of therapeutic proteins, such as monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), fusion protein biomarkers, and oligonucleotides in biological fluids and tissues. The webinar will feature a presentation by Dr Marco… Read More

Webinar date:
Supported by Evotec
#Webinars

GSK offices
#Allergy #GSK #Mergers and acquisitions #Monoclonal antibodies #RAPT Therapeutics

GSK expands food allergy pipeline with RAPT purchase

GSK has entered a definitive agreement to acquire RAPT Therapeutics, a clinical-stage biopharmaceutical company developing novel therapies for inflammatory and immunologic diseases.   The acquisition includes ozureprubart, a long-acting anti-immunoglobulin E (IgE) monoclonal antibody, currently in Phase IIb clinical development for prophylactic protection against food allergens.  Under the terms of the… Read More

#Business & Investment #News

#Bill & Melinda Gates Foundation #Biologics #Evotec #Funding #Infectious diseases #Monoclonal antibodies

Grant supports Evotec’s AI-driven optimisation of mAbs

Evotec subsidiary Just – Evotec Biologics has received a new grant from the Gates Foundation to enable global access to biotherapeutics utilising its molecular design suite of computational technologies, called J.MD.  The investment continues the support for selected Gates Foundation grantees to improve the developability and reduce the cost of… Read More

#Business & Investment #News

Overweight man clutching his knee
#Arthritis #Eli Lilly #Monoclonal antibodies #Obesity #Phase III trial #Weight loss

Combination therapy moves the needle in arthritis and obesity

Lilly’s Taltz (ixekizumab) and Zepbound (tirzepatide) used together have been shown to deliver superior efficacy in first-of-its-kind Phase IIIb trial for adults with active psoriatic arthritis (PsA) and obesity or who are overweight.  At 36 weeks, treatment with concomitant Taltz and Zepbound met the primary and all… Read More

#News #Trending News

Monoclonal antibody
#Acute inflammatory conditions #Autoimmune disease #Clinical trial #Monoclonal antibodies

Nucleome to develop first-in-class monoclonal antibody 

Biotechnology company Nucleome Therapeutics is set to advance a potential first-in-class treatment for major chronic inflammatory diseases.  NTP464 is a potential first-in-class monoclonal antibody agonist with strong potency, selectivity and developability characteristics. Nucleome has nominated NTP646 for development.  The target of NTP464 is a novel inflammation checkpoint identified using Nucleome’s proprietary suite of… Read More

#News

#Antibody-based therapeutics #Interview #Lyme Disease #Monoclonal antibodies #Tonix Pharmaceuticals

Is monoclonal antibody prophylaxis the answer to the growing threat of Lyme?

Diana Turner catches up with Seth Lederman, Co-Founder, CEO and Chairman of Tonix Pharmaceuticals, about the company’s new preventative monoclonal antibody therapy for Lyme disease.  DT: For anyone who hasn’t come across the disease before, what is Lyme disease and how is it contracted? SL: Lyme disease is a tick‑borne… Read More

#Exclusive Content

Bispecific antibodies
#Bispecific Antibodies #Celldex #Fibrosis #Monoclonal antibodies #Phase I trial

CDX-622 demonstrates sustained mast cell inhibition

Celldex has revealed positive data from the ongoing Phase I study of CDX-622, a novel bispecific antibody that targets two non-redundant, complementary pathways implicated in inflammation and fibrosis.  These pathways are mast cell depletion via stem cell factor (SCF) starvation and neutralisation of the alarmin thymic stromal… Read More

#News